While elevated LCN2 levels in serum or tumor tissue have been proposed as diagnostic or prognostic biomarkers in BC, there are no standardized thresholds, detection methods or prospective clinical trials validating its utility in TNBC. This evidence concerns the gene LCN2 and breast cancer.